GlaxoSmithKline (NYSE: GSK) is teaming up with Amicus Therapeutics (Nasdaq: FOLD) to develop a treatment for Fabry disease, an inherited disorder.

GSK said Friday that it is paying Amicus, which is based in New Jersey, an upfront fee of $30 million plus potential milestone and commercialization fees of $170 million.

The drug giant also is paying $31 million for a 20 percent ownership stake in Amicus.

The deal is the latest in a series made by GSK that target rare disorders. Earlier this month, GSK said it would

The Amicus drug Amigal is currently in Phase III clinical trial.

"This strategic collaboration is another significant milestone in delivering our vision for GSK Rare Diseases. Amicus’ scientific and clinical expertise in human genetic diseases is among the best in the industry, and we are pleased to be collaborators and investors in this exceptional company" said Marc Dunoyer, global head of GSK Rare Diseases, in a statement.

"Our focus now is to continue to advance Amigal for Fabry disease and it is our hope to deliver a first-in-class, oral medicine to the thousands of people worldwide living with this devastating rare disease,” he added.

Fabry can cause pain, kidney failure and increased risk of heart attack and stroke. It affects some 5,000 to 10,000 people worldwide, GSK said.

GSK operates its U.S. headquarters in RTP.

Get the latest news alerts: at Twitter.